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Objectives: Prevalence of diabetes mellitus is increasing globally in most developed 
and developing countries and Dipeptidyl peptidase-4 inhibitors (Gliptins) are recently 
introduced class of drugs for type 2 diabetes mellitus which shows good glycemic 
control. It is a prospective interventional pilot study aimed to determine the efficacy 
of add-on vildagliptin therapy to metformin in type 2 diabetes mellitus patients for 
a period of 6 months in south Indian resource limited settings. MethOds: A total 
of 185 patients were enrolled into the study. The study subjects were assigned into 
three groups based on their existing treatment (initiated within one month) i.e., group 
I (vildagliptin and metformin), group II (vildagliptin alone) and group III (metformin 
alone). They were also assessed for baseline demographic characteristics. Medication 
adherence was measured to ensure that patients are complies with the treatment. 
The clinical endpoint was estimated by using various variables like quality of life and 
other clinical endpoints such as RBS, PPBS after three months of specific treatment 
through direct interview and by referring the medical case records. Results: The 
results show that there is no significant difference in individual groups in terms of 
demographic characteristics. (P > 0.01). And all the present study subjects are found to 
have more than 90 % of medication adherence. We observed high level of significant 
improvement in group I (93.18±3.76) subjects whereas low level of improvement in 
group III subjects (90.4±4.13) after the relevant treatment (P = 0.003). Group I subjects 
are also found to have good glycaemic control (RBS, FBS and PPBS) than any other 
treatment groups P< 0.01). cOnclusiOns: Add on vildagliptin therapy to metformin 
might improve the quality of life of type 2 diabetes mellitus patients and might be 
useful to bring the glycemic levels under control in type 2 diabetic patients in South 
Indian resource limited settings.
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Objectives: To evaluate the accuracy of different blood glucose determination meth-
ods, and provide a theoretical basis for governments to determine the mainstream 
glucose detection methods. MethOds: The MEDLINE, EMBASE, EBM REVIEWS, CBM, 
CNKI, Wanfang, Google academic search et al were were retrieved for literatures col-
lection, literature quality evaluation was implemented by using QUADAS criteria, 
meta-analysis was carried out using Stata11.0 and heterogeneity test and sensitivity 
analysis was implemented. Results: 20 studies were included, which contained a 
total of 2681 cases of patients. Meta analysis showed that values measured by the 
dry chemical method were significantly higher than glucose oxidase method, and 
no significant differences was found with the hexokinase method, no significant 
differences was yet found between the electrode method with enzyme method, the 
MD (95%CI) were 0.31 (0.09, 0.53), -0.51 (-0.14, 1.17) and -0.13, (-0.27, 0.02) respectively. 
Sensitivity analysis of the model, the sample source, research population, equip-
ment and countries was carried out and conclusion was found no change between 
the methods. cOnclusiOns: there was significant difference between different 
blood glucose detection methods; application of dry chemical measurement results 
should be cautious, we recommend using the glucose oxidase or diagnosis hexoki-
nase method.
PDB6
EffEctiVEnEss Of hErBOtriM anD MuniPraBha in thE ManagEMEnt Of 
hyPOthyrODisM
Acharya S1, Mateti UV2, Nagappa AN2
1Muniyal Institute of Ayurveda Medical Sciences, Muniyal, India, 2Department of Pharmacy 
Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
Objectives: Hypothroidism is treated by replacement therapy of levothyroxine in 
allopathic system of medicine needs to be taken through out life time. In Ayurveda 
an ethnic system of Indian medicine has a remedy based on the drugs of natural ori-
gin which showes improved thyroid function. In this study the patients are treated 
for Hypothroidism with combination of two proprietary medicines (herbotrim and 
Muniprabha) of Muniyal Ayurveda Pharmacy, Manipal. MethOds: Thirty cases 
Hypothyroidism are selected from Inpatients and Out patients of Muniyal Ayurveda 
Hospital, Manipal after obtaining the consent of the patients. The study was 
approved by intitutional ethics committe. The study design consited of observation 
before and after teatment with Herbotrim 2-0-2 (2 BID) with water and Muniprabha 
1-1-1 (1TID) with water, tablets along with concomitant medicines for a period of 
3 months. The subjective Obesity, Brady cardia, Somnolence, Slow mentationand 
objective criteria of assessment were T3, T4, TSH, Hb% and cholesterol. Results: 
The Mean palsma T3 (mcg/dl) levels were 33.4 to 105.4, T4 (mcg/dl) levels were 2.38 
to 11.36 and TSH (micro IU/ml) levels were109.4 to 6.63. The hemoglobin (g%) levels 
were increased from 10.05 to 12.24 and serum cholesterol (mg%) leveles were drop-
ded from 280 to 158.9. cOnclusiOns: Considerable improvement was observed in 
both subjective and objective criteria of assessment. There was decrease in subjec-
tive criteria like – Obesity, Brady cardia, Somnolence, Slow mentation, etc. There 
was increase in T3 and T4, and nd Hb%. The decrease in TSH and cholesterol with 
Herbotrim and Muniprabha in Hypothyroidism patients.
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Objectives: To examine the association between incretin-based therapies and 
the risk of pancreatitis. MethOds: We searched Medline, Embase, CENTRAL and 
ClinicalTrials.gov to identify randomized controlled trials (RCTs), non-randomized 
clinical trials, cohort studies, and case-control studies of adults with type 2 diabe-
tes mellitus that compared glucagon-like peptide-1 (GLP-1) receptor agonists or 
dipeptidyl peptidase-4 (DPP-4) inhibitors against placebo or active anti-diabetic 
medications. Trained reviewers, working in pairs, independently screened for eli-
gible studies, assessed risk of bias, and extracted data. Results: We included 59 
studies (n= 348,624), consisting of 55 RCTs (n= 33,350) and 4 observational studies 
(n= 315,274). Pooled estimates of 55 RCTs (at low or moderate risk of bias involv-
ing 37 pancreatitis events, raw event rate 0.11%) did not suggest increased risk 
of pancreatitis between incretin agents versus control (Peto OR 1.11, 95% CI 0.57 
to 2.17). Estimates by type of incretin agents suggested similar results (GLP-1 
agonists vs. control: OR 1.05, 95% CI 0.37 to 2.94; DPP-4 inhibitors vs. control: 
OR 1.06, 95% CI 0.46 to 2.45). Three retrospective cohort studies (moderate to high 
risk of bias involving 1466 pancreatitis events, raw event rate 0.47%) also did not 
suggest increased risk of pancreatitis associated with either exenatide (adjusted 
OR 0.93, 95% CI 0.63 to 1.36 in one study, adjusted hazard ratio (HR) 0.9, 95% CI 
0.6 to 1.5 in another) or sitagliptin (adjusted HR 1.0, 95% CI 0.7 to 1.3). However, 
a matched case-control study with moderate risk of bias suggested that the use 
of either sitagliptin or exenatide was associated with increased odds of acute 
pancreatitis (adjusted OR 2.07, 95% CI, 1.36 to 3.13). cOnclusiOns: The available 
evidence suggests that the risk of pancreatitis in patients using incretin agents 
is very low, and does not support for the hypothesis that incretins increase the 
risk of pancreatitis.
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Objectives: This study evaluated the effect of anti-thyroid drugs and thyroid-
ectomy on response of hyperthyroidism to fixed doses of Radioactive Iodine 
Therapy (RAI) and the incidence of hypothyroidism at 6months post RAI ther-
apy. MethOds: A retrospective review of the medical records of 42 hyperthyroid 
patients treated with radioiodine to evaluate response rate of hyperthyroidism 
to two fixed dose regimens of 370 MBq (10 mCi) and 555 MBq (15 mCi) RAI ther-
apy was carried out. The impacts of thyroidectomy and ant-thyroid drug pre-
treatment were documented. The treatment goal is to cure hyperthyroidism by 
rendering the patient either euthyroid or hypothyroid, within 6months of single 
dose of 370 MBq (10 mCi) or 555 MBq (15 mCi) RAI therapy. Statistical analysis was 
with SPSS version 15.0 and the level of statistical significance was taken as P < 
0.05. Results: The response (i.e. hypothyroid and euthyroid) at 6months post RAI 
for both doses of radioiodine was 71.4%, and after re-treatment of 7 patients who 
were earlier hyperthyroid after 6months, the response rate soared to 95.2%. The 
incidence of hypothyroidism (TSH > 6.1 mIU/L) was 47.6% with patients who had 
received 370 MBq (10 mCi) and 38.1% with those that received 555 MBq (15 mCi) 
radioiodine therapy. The use of anti-thyroid drugs (carbimazole or methima-
zole only) as pre-treatment increased response to RAI; Propylthiouracil however 
blocked response to RAI therapy in one patient Thyroidectomy, either total or 
subtotal, increased the response to RAI treatment. cOnclusiOns: Radioactive 
iodine is highly effective for the treatment of Graves’ hyperthyroidism, with a very 
high cure rate. Pretreatment with some anti-thyroid drugs protects against wors-
ening of thyrotoxicosis after radioiodine and increases response to RAI therapy. 
Thyroidectomy increases the response to RAI treatment. However, the incidence 
of hypothyroidism should be anticipated and well prepared for as part of the 
treatment protocol.
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Objectives: To systematically review the effectiveness and safety of premixed 
insulin lispro and insulin glargine in type 2 diabetes. MethOds: Such databases as 
PubMed, EMBASE, The Cochrane Library, ClinicalTrials.gov, CBM, CNKI and WanFang 
were searched for relevant studies from inception to October, 2013. Two review-
ers independently screened studies according to exclusion and inclusion criteria, 
extracted data and assessed the methodological quality. Then, meta-analysis was 
performed using RevMan 5.2 software. Results: 13 RCTs involving 4267 patients 
were included. The results of meta-analysis showed that, compared to insulin 
glargine, premixed insulin lispro effectively improved HbA1c levels [WMD= -0.18, 
95%CI (-0.33, -0.02), P= 0.03(parallel trials), WMD= -0.38,95%CI(-0.52,-0.24), P< 0.00001 
(cross-over trials)]. However, insulin glargine effectively improved FPG levels 
[WMD= 0.82,95%CI(0.65, 0.99), P< 0.00001 (parallel trials)]; WMD= 0.64,95%CI(0.26, 
1.02), P= 0.0009 (cross-over trials)], weight gain[WMD= 0.93, 95%CI(0.31,1.56), 
P= 0.003 (parallel trials); WMD= 0.74, 95%CI(0.19,1.29), P= 0.009(cross-over trials)] 
and decrease hypoglycemia incidence[OR= 1.26, 95%CI(1.10, 1.45), P= 0,0007(paral-
lel trials), OR= 2.24, 95%CI(1.45, 3.46), P= 0.0003(cross-over trials)]. cOnclusiOns: 
: Premixed insulin lispro and insulin glargine have different advantages in clinical 
efficacy. Doctors should select the appropriate insulin treatment according to the 
patient’s health condition and efficacy target.
